При повышеном холестерине давление понижается
О сайте

Лечение гипотонии и головокружения в пожилом возрасте

Самое лучшее
Лечение гипотонии и головокружения в пожилом возрасте
|| 27 January 2015, 23:59

Aarsland, D., Larsen, J. P., Cummins, J. L., et al (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson’s disease: a community based study. Archives of Neurology, 56, 595–601.

Agьera-Ortiz, L. & Reneses-Prieto, B. (1999) The place of non-biological treatments. In Late Onset Schizophrenia (eds R. Howard, P. V. Rabins & D. J. Castle), pp. 50–56. Winchester: Wrightson Biomedical Publishing.

American Psychiatric Association (2000) Diagnostic and Statis-tical Manual of Mental Disorders (4th edn, text revision) (DSM–IV–TR). Washington, DC: APA.

Avron, J. & Gurwitz, J. (1990) Principles of pharmacology. In Geriatric Medicine (2nd edn) (eds K. Cassel, D. Reisenberg, L. Sorenson, et al), pp. 66–77. New York: Springer-Verlag.

Barak, Y., Wittenberg, N., Naor, S., et al (1999) Clozapine in elderly psychiatric patients: tolerability, safety and efficacy. Comprehensive Psychiatry, 40, 320–325.

Bartels, S. J., Forester, B., Mueser, K. T., et al (2004) Enhanced skills training and health care management for old persons with severe mental illness. Community Mental Health Journal, 40, 75–90.

Bassiony, M. M., Steinberg, M. S., Warren, A., et al (2000) Delusions and hallucinations in Alzheimer ’s disease: prevalence and clinical correlates. International Journal of Geriatric Psychiatry, 15, 99–107.

Bergman, J. & Lerner, V. (2002) Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clinical Neuropharmacology, 25, 107–110.

Breier, A., Sutton, V. K., Feldman, P. D., et al (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biological Psychiatry, 52, 438–445.

Brodaty, H., Ames, D., Snowdon, J., et al (2003) A randomised placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Journal of Clinical Psychiatry, 64, 134–143.

Bullock, R. & Cameron, A. (2001) Rivastigmine for the treatment of dementia and visual hallucinations associated with Par-kinson’s disease: a case series. Current Medical Research and Opinion, 18, 258–264.

Byrne, J. (1997) Lewy body dementia. Journal of the Royal Society of Medicine, 90 (suppl. 32), 14–15.

Byrne, E. J., Burns, A. & Waite, J. (1992) Neuroleptic sensitivity in dementia with cortical Lewy bodies. BMJ, 305, 1158–1159.

Camberg, L., Woods, P., Ooi, W. L., et al (1999) Evaluation of simulated presence: a personalized approach to enhance well being in persons with Alzheimer’s disease. Journal of the American Geriatrics Society, 47, 446–452.

Cohen, C. I., Cohen, G. D., Blank, K., et al (2000) Schizophrenia and older adults: an overview. Directions for research and policy. American Journal of Geriatric Psychiatry, 8, 19–28.

Cohen-Mansfield, J. (2003) Non-pharmacological interventions for psychotic symptoms in dementia. Journal of Geriatric Psychiatry and Neurology, 16, 219–224.

Cummings, J. L., Street, J., Masterman, D., et al (2002) Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dementia and Geriatric Cognitive Disorders, 13, 67–73.

De Deyn, P. P., Rabheru, K., Rasmussen, A., et al (1999) A randomised trial of risperidone, placebo and haloperidol for behavioural symptoms of dementia. Neurology, 53, 946–955.

Devanand, D. P., Marder, K., Michaels, K. S., et al (1998) A randomised, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviours in Alzheimer’s disease. American Journal of Psychiatry, 155, 1512–1520.

Duff, G. (2004) Atypical Antipsychotic Drugs and Stroke: Message from Professor Gordon Duff, Chairman, Committee on Safety of Medicines (CEM/CMO/2004/1). http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/safetymessages/antipsystroke_9304.htm

Fabbrini, G., Barbanti, P., Aurilia, C., et al (2002) Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurological Science, 23, 41–43.

Fergusson, E. & Howard, R. (2000) Donepezil for the treatment of psychosis in dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 15, 280–281.

Finkel, S. I. (2004) Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer ’s disease. Clinical Therapeutics, 26, 980–990.

Förstl, H., Burns, A., Levy, R., et al (1994) Neuropathological correlates of psychotic phenomena in confirmed Alzheimer’s disease. British Journal of Psychiatry, 165, 53– 59.

Fowler, D., Garety, P. & Kuipers, E. (1995) Cognitive behavioural therapy for psychosis: theory and practice. Chichester: John Wiley & Sons.

Frost, J. B. (1969) Paraphrenia and paranoid schizophrenia. Psy-chiatrica Clinica, 3, 129–138.

Garety, P., Kuipers, E., Fowler, D., et al (1994) Cognitive–beha-vioural therapy for drug resistant psychosis. British Journal of Psychology, 67, 259–271.

Giladi, N., Treves, T. A., Paleacu, D., et al (2000) Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease. Journal of Neural Transmission, 107, 59–71.

Gilley, D. W., Wilson, R. S., Beckett, L. A., et al (1997) Psychotic symptoms and physically aggressive behaviour in Alzheimer’s disease. Journal of the American Geriatrics Society, 45, 1074–1079.

Hall, L. & Hare, J., (1997) Video respite for cognitively impaired persons in nursing homes. American Journal of Alzheimer’s Disease and Other Dementias, 12, 117–121.

Herrmann, N., Mamdani, M. & Lanctot, K. L. (2004) Atypical antipsychotics and risk of cerebrovascular accidents. American Journal of Psychiatry, 161, 1113–1115.

Hirose, T., Uwahodo, Y., Yamada, S., et al (2004) Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. Journal of Psychopharma-cology, 18, 375–383.

Hoeh, N., Gyalai, L., Weistraub, D., et al (2003) Pharmacological management of psychosis in the elderly. A critical review. Journal of Geriatric Psychiatry and Neurology, 16, 213–218.

Holmes, C., Fortenza, O., Powell, J., et al (1997) Do neuroleptic drugs hasten cognitive decline in dementia? Carriers of apolipoprotein E epsilon 4 allele seem particularly sus-ceptible to their effects. BMJ, 10, 1411; author reply 1412.

Howard, R. (2002) Late-onset schizophrenia and very late-onset schizophrenia-like psychosis. In Psychiatry in the Elderly (eds R. Jacoby & C. Oppenheimer), pp. 744–761. Oxford: Oxford University Press.

Howard, R. & Levy, R. (1992) Which factors affect treatment response in late paraphrenia? International Journal of Geriatric Psychiatry, 7, 667–672.

Howard, R., Rabins, P. V., Seeman, M. V., et al (2000) Inter-national Late-onset Schizophrenia Group. Late-onset schizo-phrenia and very-late-onset schizophrenia-like psychosis: an international consensus. American Journal of Psychiatry, 157, 172–178.

Jaskiw, G. E., Thyrum, P. T., Fuller, M. A., et al (2004) Phar-macokinetics of quetiapine in elderly patients with select psychotic disorders. Clinical Pharmacokinetics, 43, 1025–1035.

Jeste, D. V. (2004) Tardive dyskinesia rates with atypical anti-psychotics in older adults. Journal of Clinical Psychiatry, 65 (suppl. 9), 21–24.

Jeste, D. V. & Finkel, S. I. (2000) Psychosis of Alzheimer’s disea-se and related dementias. Diagnostic criteria for a distinct syndrome. American Journal of Geriatric Psychiatry, 8, 29–34.

Jeste, D. V. & Twamley, E. W. (2003) Understanding and managing psychosis in late life. Psychiatric Times, XX (3).

Jeste, D. V., Eastham, J. H., Lacro, J. P., et al (1996) Management of late-life psychosis. Journal of Clinical Psychiatry, 57 (suppl. 3), 39–45.

Kane, J. M. (1999) Prospective study of tardive dyskinesia in the elderly. In Syllabus and Proceedings of the 1999 American Psychiatric Association Annual Meeting (Abstract NO32C:79). Washington, DC: APA.

Karim, S. & Burns, A. (2003) The biology of psychosis in old people. Journal of Geriatric Psychiatry and Neurology, 16, 207–212.

Katz, I. R, Jeste, D. V., Mintzer, J. E., et al (1999) Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomised, double blind trial. Risperidone Study Group. Journal of Clinical Psychiatry, 60, 107–115.

Kay, D. W. K. & Roth, M. (1961) Environment and hereditary factors in the schizophrenias of old age (“late para-phrenia”) and their bearing on the general problem of causation in schizophrenia. Journal of Mental Science, 107, 649–686.

Kidder, S. W. (2003) Psychosis in the elderly – whose delusion is it? Geriatric Times, 4 (2), 25–26.

Kopelowicz, A. & Liberman, R. P. (1998) Psychosocial treatments for schizophrenia. In A Guide to Treatments that Work (eds P. E. Nathan & J. M. Gorman), pp. 190–211. New York: Oxford University Press.

Kuzuhara, S. (2001) Drug-induced psychotic symptoms in Par-kinson’s disease. Problems, management and dilemma. Journal of Neurology, 248 (suppl. 3), III28–III31.

Levy, M. L., Cummings, J. L., Fairbanks, L. A., et al (1999) Apolipoprotein E genotype and non-cognitive symptoms in Alzheimer’s disease. Biological Psychiatry, 165, 53–59.

Lisa, T., Zorrilla, E. & Jeste, D. (2002) Late-life psychotic disor-ders: nosology and classification. In Principles and Practices of Geriatric Psychiatry (2nd edn) (eds J. R. M. Copeland, M. T. Abou-Saleh & D. Blazer), pp. 493–496. Chichester: John Wiley & Sons.

Madhusoodanan, S., Suresh, P. & Brenner, R. (1999) Experience with the atypical anti-psychotics risperidone and olanzapine in the elderly. Annals of Clinical Psychiatry, 11 , 113–118.

Madhusoodanan, S., Brenner, R., Gupta, S., et al (2004) Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectrum, 9, 862–867.

Margallo-Lana, M., Swann, A., O’Brien, J., et al (2001) Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. International Journal of Geriatric Psychiatry, 16, 39–44.

McKeith, I. G., Fairbairn, A., Perry, R., et al (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ, 305, 673–678.

McKeith, I. G., Fairbairn, A. F., Bothwell, R. A., et al (1994) An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology, 44, 872–877.

McKeith, I. G., Galasko, D., Kosaka, K., et al (1996) Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology, 47, 1113–1124.

McKeith, I. G., Del Ser, T., Spano, P., et al (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet, 356, 2031–2036.

McKitrick, L., Camo, C. & Black, F. (1992) Prospective memory intervention in Alzheimer’s disease. Journal of Gerontology, 47, P337–P343.

McManus, D. Q., Arvanitis, L. A. & Kowalcyk, B. B. (1999) Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Journal of Clinical Psychiatry, 60, 292–298.

McQuaid, J. R., Granhoolm E., McClure, F. S., et al (2000) Development of an integrated cognitive–behavioural and social skills training intervention for older people with schizophrenia. Journal of Psychotherapy Practice and Research, 9 , 149–156.

McShane, R., Keene, J., Gedling, K., et al (1997) Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ, 314, 266–270.

Mintzer, J. & Targum, S. D. (2003) Psychosis in elderly patients: classification and pharmacotherapy. Journal of Geriatric Psychiatry and Neurology, 16, 199–206.

Mowat, D., Fowlie, D. & MacEwan, T. (2004) CSM warning on atypical psychotics and stroke may be detrimental for dementia. BMJ, 328, 1262.

Ondo, W. G., Levy, J. K., Vuong, K. D., et al (2002) Olanzapine treatment for dopaminergic-induced hallucinations. Move-ment Disorders, 17, 1031–1035.

Цstling, S. & Skoog, I. (2002) Psychotic symptoms and paranoid ideation in a non-demented population-based sample of the very old. Archives of General Psychiatry, 59, 53–59.

Overshott, R., Byrne, J. & Burns, A. (2004) Nonpharmaco-logical and pharmacological interventions for symptoms in Alzheimer’s disease. Expert Review of Neurotherapeutics, 4, 809–821.

Palmer, B. W., McClure, F. S. & Jeste, D. V. (2001) Schizo-phrenia in late life: findings challenge traditional concepts. Harvard Review of Psychiatry, 9, 51–58.

Post, F. (1966) Persistent Persecutory States of the Elderly. Oxford: Pergamon Press.

Royal College of Psychiatrists, Royal College of General Practi-tioners, British Geriatrics Society, et al (2004) Guidance for the Management of Behavioural and Psychiatric Symptoms in Dementia and the Treatment of Psychosis in People with History of Stroke/TIA Following CSM Restriction on Risperidone and Olanzapine. London: Faculty of the Psychiatry of Old Age, Royal College of Psychiatrists. http://www.rcpsych.ac.uk/college/faculty/oap/professional/guidance_summary.htm

Sajatovic, M., Perez, D., Brescan, D., et al (1998) Olanzapine therapy in elderly patients with schizophrenia. Psycho-pharmacology Bulletin, 34, 819–823.

Schneider, L. S. (1996) Meta-analysis of controlled pharmacologic trials. International Psychogeriatrics, 8 (suppl. 3), 375–379; discussion 381–382.

Schneider, L. S., Olin, J. T., Doody, R. S., et al (1997) Validity and reliability of the Alzheimer ’s Disease Cooperative Study — Clinical Global Impression of Change. The Alzhei-mer’s Disease Cooperative Study. Alzheimer Disease and Associa-ted Disorders, 11 (suppl. 2), S22–S32.

Steele, C., Rovner, B., Chase, G. A., (1990) Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. American Journal of Psychiatry, 147, 1049–1051.

Stern, Y., Tang, M. X., Albert, M. S., et al (1997) Predicting time to nursing home care and death in individuals with Alzheimer’s disease. JAMA, 277, 806–812.

Street, J. S., Clark, W. S., Gannon, K. S., et al (2000) Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomised, placebo-controlled trial. The HGEU Study Group. Archives of General Psychiatry, 57, 968–976.

Street, J. S., Clark, W. S., Kadam, D. L., et al (2001) Long-term efficacy of olanzapine in the control of psychotic and beha-vioral symptoms in nursing home patients with Alzheimer’s dementia. International Journal of Geriatric Psychiatry, 16 (suppl. 1), S62–S70.

Targum, S. D. (2001) Treating psychotic symptoms in elderly patients. Primary Care Companion to the Journal of Clini-cal Psychiatry, 3, 156–163.

Targum, S. D. & Abbott, J. L. (1999) Pyschosis in the elderly: a spectrum of disorders. Journal of Clinical Psychiatry, 60 (suppl. 8), 4–10.

Tariot, P. N. (1995) Behaviour Rating Scale for Dementia. American Journal of Psychiatry, 152, 1349–1357.

Tariot, P. N., Salzman, C., Yeung, P. P., et al (2000) Long-term use of quetiapine in elderly patients with psychotic disorders. Clinical Therapeutics, 22, 1068–1084.

Tsuang, M. M., Lu, L. M., Stotsky, B. A., et al (1971) Haloperidol versus thioridazine for hospitalised psycho-geriatric patients: double blind study. Journal of the American Geriatrics Society, 19, 593–600.

Tune, L. E. & Salzman, C. (2003) Schizophrenia in late life. Psychiatric Clinics of North America, 26, 103–113.

Walker, Z., Grace, J., Overshot, R., et al (1999) Olanzapine in dementia with Lewy bodies: a clinical study. International Journal of Geriatric Psychiatry, 14, 459–466.

Wolters, E. C. (2001) Intrinsic and extrinsic psychosis in Parkinson’s disease. Journal of Neurology, 248 (suppl. 3), III22–III27.

Wolters, E. C. & Berendse, H. W. (2001) Management of psycho-sis in Parkinson’s disease. Current Opinion in Neurology, 14, 499–504.

Wood, K. A., Harris, J., Morreale, A., et al (1988) Drug-induced psychosis and depression in the elderly. Psychiatric Clinics of North America, 11, 167–193.

World Health Organization (1992) The ICD–10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO.

Wynn, Z. J. & Cummings, J. L. (2004) Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer ’s disease. Dementia and Geriatric Cognitive Disorders, 17, 100–1008.

Yeung, P. P., Tariot, P. N., Schneider, L. S., et al (2000) Quetia-pine for elderly patients with psychotic disorders. Psychi-atric Annals, 30, 197–203.

Zarit, S. H., Todd, P. A. & Zarit, J. M. (1986) Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist, 26, 260–266.

Zayas, E. M. & Grossberg, G. T. (1998) The treatment of psy-chosis in late life. Journal of Clinical Psychiatry, 59 (suppl. 1), 5–12.

Zayas, E. M. & Grossberg, G. T. (2002) Treatment of late-onset psychotic disorders. In Principles and Practices of Geriatric Psychiatry (2nd edn) (eds J. R. M. Copeland, M. T. Abou-Saleh & D. Blazer), pp. 511–525. Chichester: John Wiley & Sons.

Источник: http://psyobsor.org/1998/30/5-1.html

Лечение гипотонии и головокружения в пожилом возрасте